Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. (July 2014)

• Record Type: Journal Article
• Authors: van Vugt, Vincent A; Piccioni, David E; Brown, Bradley D; Brown, Tiffany; Saria, Marlon G; Juarez, Tiffany; Kesari, Santosh
• Is Part Of: CNS oncology. Volume 3:Number 4(2014)
• Page Start: 257
• Page End: 265
• Publication Date: 2014-07
• Subjects: alternative regimens -- chemotherapy -- glioblastoma -- glioma temodar -- safety -- temozolomide; Central nervous system -- Tumors -- Periodicals; 616.99481
• DOI: 10.2217/cns.14.29
• Languages: English
• ISSNs: 2045-0907

Abstract

SUMMARY : Aims: We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.Patients & methods: Fifteen adult patients were treated; 14 were treated with 300 mg/m 2 and one treated with 250 mg/m 2 .Results: We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.Conclusion: The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.